Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 10/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3260323 | 0.83 | CHRNB2 (0.35) | CHRNB2CHRNA5CHRNA7CHRNA4SIGMAR1 | |
| SCHEMBL2267046 | 0.83 | CHRNB2 (0.35) | CHRNB2CHRNA5CHRNA7CHRNA4SIGMAR1 | |
| SCHEMBL2267050 | 0.83 | CHRNB2 (0.35) | CHRNB2CHRNA5CHRNA7CHRNA4SIGMAR1 | |
| SCHEMBL3379114 | 0.78 | NLRP3 (0.35) | CHRNB2CHRNA5CHRNA7CHRNA4SIGMAR1 | |
| SCHEMBL25957050 | 0.73 | HDAC8 (0.32) | SIGMAR1 | |
| SCHEMBL18579024 | 0.70 | CHRM3 (0.34) | CHRM3CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL8968168 | 0.70 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL26786826 | 0.69 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL27797919 | 0.68 | FFAR1 (0.37) | — | |
| SCHEMBL25803032 | 0.68 | CHRNB2 (0.32) | CHRNB2CHRNA7CHRNA4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244615-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |